checkAd

     1095  0 Kommentare CLINUVEL expands DNA Repair Program - Seite 3

    SCENESSE and PRÉNUMBRA are registered trademarks of CLINUVEL PHARMACEUTICALS LTD.

    Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD

    Media enquiries
    Monsoon Communications
    Mr Rudi Michelson, 61 411 402 737, rudim@monsoon.com.au

    Head of Investor Relations
    Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

    Investor Enquiries
    https://www.clinuvel.com/investors/contact-us

    Forward-Looking Statements
    See CLINUVEL’s website for details. www.clinuvel.com.

     



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    CLINUVEL expands DNA Repair Program - Seite 3 SCENESSE (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) MELBOURNE, Australia, March 24, 2021 (GLOBE NEWSWIRE) - CLINUVEL has expanded its clinical program to evaluate the DNA reparative potential of afamelanotide in …